<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=28458></link><description><![CDATA[Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 15:35:20 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2017/01/3698601005_20170110104817_8422278163.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Takeda to Acquire ARIAD Pharmaceuticals, Inc.]]></title><link>https://www.newswire.co.kr/newsRead.php?no=843253</link><description><![CDATA[CAMBRIDGE, Mass. & OSAKA, Japan--(Business Wire/Korea Newswire)--Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) and ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) (“ARIAD”) today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The trans...]]></description><pubDate>Tue, 10 Jan 2017 10:50:00 +0900</pubDate></item></channel></rss>